How to improve the design of trials of antifungal prophylaxis among neutropenic adults with acute leukemia

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 4, 2004, Pages

  Menichetti, Francesco ^a  

^a CISANELLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; IDARUBICIN; ITRACONAZOLE;

ACUTE LEUKEMIA; ANTIFUNGAL PROPHYLAXIS; ASPERGILLOSIS; CANDIDIASIS; CELLULAR IMMUNITY; CENTRAL VENOUS CATHETER; CHEMOTHERAPY; DRUG BLOOD LEVEL; FUNGAL COLONIZATION; GASTROINTESTINAL TRACT; HUMAN; INFECTION PREVENTION; METHODOLOGY; MOUTH CAVITY; MYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

ACUTE DISEASE; ADULT; ANTIFUNGAL AGENTS; CLINICAL TRIALS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; LEUKEMIA; MYCOSES; NEUTROPENIA; RESEARCH DESIGN;

EID: 12844254325     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421954     Document Type: Review

References (20)

1. Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28:331-40.
2. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
3. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999; 28:250-5.
4. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
5. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
6. Morgenstern GR, Prentice AG, Prentice HG, et al. A randomised controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies: UK Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105:901-11.
7. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematologic malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44:1887-93.
8. Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. Clin Oncol 2003; 21:4615-26.
9. Vreugdenhil G, Van Dijke BJ, Donnelly P, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with haematological malignancies and intensive chemotherapy. A double-blind, placebo controlled study. Leuk Lymphoma 1993; 11:353-8.
10. Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30:300-5.
11. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leucemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994; 120:913-8.
12. Prentice HG, Caillot D, Dupont B, Menichetti F, Schuler U. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: meeting report. Acta Haematol 1999; 101:56-62.
13. Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections - all neutropenic patients are not the same. Clin Infect Dis 1994; 18:793-8.
14. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal diseases in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995; 21:361-9.
15. Sandford GR, Merz WG, Wingard JR, Charache P, Saral R. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142:503-9.
16. Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol 1987; 6:628-33.
17. Martino P, Girmenia C, Venditti M, et al. Prospective study of Candida colonization and systemic infection in neutropenic patients: a retrospective study. Cancer 1989; 64:2030-4.
18. Martino P, Girmenia C, Micozzi A, De Bernardis F, Boccanera M, Cassone A. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur J Clin Microbiol Infect Dis 1994; 13:797-804.
19. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 1995; 86:2063-72,
20. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.